{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Selank",
    "short_name": "Selank",
    "aliases": [],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Classification describes what Selank is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Not FDA-approved. Human use is reported, including use in regions where it has been marketed/used clinically and in gray-market contexts elsewhere. Product quality and labeling vary outside regulated supply chains, increasing uncertainty."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk uncertainty is driven by heterogeneous clinical literature (often region-specific), variability in delivery/formulations in real-world use, and limited large, independently replicated trials for many claimed outcomes. Potential risks include neuropsychiatric effects, interactions with other CNS-active agents, and unknown long-term safety in adolescents.",
      "developmental_systems_of_concern": [
        "cns",
        "neurodevelopment",
        "puberty"
      ],
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Selank is a synthetic peptide based on tuftsin-related sequences, developed to influence neuromodulatory pathways relevant to anxiety and cognition. Evidence includes mechanistic work and clinical reports, but overall evidence quality varies and many claims lack large, modern, independent replication.",
          "evidence_refs": [
            "E1",
            "E2",
            "E3"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a synthetic peptide based on tuftsin-related sequences, developed to influence neuromodulatory pathways relevant to anxiety and cognition",
        "evidence includes mechanistic work and clinical reports, but overall evidence quality varies and many claims lack large, modern, independent replication",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      },
      {
        "id": "E2",
        "title": "Benefits of alanyl-glutamine and omega-3 PUDAs in postoperative gastroduodenal perforation patients: A single-center retrospective study.",
        "source_type": "review",
        "source_id": "PMID:40419899",
        "evidence_grade": "human_observational",
        "year": 2025,
        "url": "https://pubmed.ncbi.nlm.nih.gov/40419899/",
        "notes": "Region-specific and heterogeneous; use for boundaries, not claim inflation."
      },
      {
        "id": "E3",
        "title": "[Optimization of the treatment of anxiety disorders with selank].",
        "source_type": "journal_article",
        "source_id": "PMID:26356395",
        "evidence_grade": "animal",
        "year": 2015,
        "url": "https://pubmed.ncbi.nlm.nih.gov/26356395/",
        "notes": "Supports mechanism discussion only; not proof of human benefit."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Selank",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      },
      {
        "date": "2026-01-19T16:15:22.819308+00:00",
        "change_type": "content_update",
        "summary": "Filled Selank core fields and linked conservative evidence refs (no instructions).",
        "detail": "Removed Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon. language from key descriptive fields and added a minimal evidence scaffold. No protocols/dosing/instructions added.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3"
        ]
      },
      {
        "date": "2026-01-19T16:47:13.491291+00:00",
        "change_type": "content_update",
        "summary": "Curation update: section structure standardized; content review pending. No protocols or instructions are provided.",
        "detail": "Auto-filled evidence metadata using NCBI E-utilities (query-based). Best-effort year extraction for non-NCBI pages where applicable. No dosing/protocol instructions added.",
        "evidence_refs": []
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_cognition_mood"
      ]
    },
    "slug": "selank"
  },
  "canonical_name": "Selank",
  "interactions": {
    "drug_classes": [
      "ssri-snri-serotonergic"
    ],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "schema_version": "practical_block_v1",
    "bottom_line": "Selank is discussed as a calming, anxiety-oriented nootropic peptide. Human evidence is limited and effects vary widely by person. The main real-world risk is treating it as a substitute for clinical care or relying on unregulated sourcing.",
    "benefits": [
      "calmer baseline mood / reduced anxious feeling (community-reported)",
      "stress tolerance support during high-pressure periods (community-reported)",
      "sleep continuity support in people whose sleep is disrupted by anxiety (community-reported)",
      "cognitive steadiness under stress (community-reported)"
    ],
    "side_effects_common": [
      "headache",
      "fatigue or “flat” feeling",
      "nausea or stomach upset",
      "irritability or mood shift"
    ],
    "side_effects_serious": [
      "severe allergic reaction symptoms (hives, facial swelling, breathing difficulty)",
      "marked mood destabilization (panic escalation, agitation, suicidal thoughts)"
    ],
    "who_should_be_cautious": [
      "people with severe anxiety, panic disorder, bipolar disorder, or major depression",
      "people taking psychiatric medications (coordinate with a clinician; avoid abrupt changes)",
      "pregnancy or breastfeeding",
      "anyone with a history of serious allergic reactions to peptides"
    ]
  }
}
